If you are:
Not Recommended: INSUFF HUMAN DATA AVAIL; ANIMAL DATA SHOW DEVELOPMENTAL TOXICITY IN 2ND/3RD TRIM
Precaution: INSUFF HUMAN DATA; EXCRETED IN RATS, DATA SUGGEST RISK TO KIDNEY DEVELOPMENT
An adult over 60:
management or monitoring precaution: Cardiovascular-Reduced intravascular volume incr. risk of hypotension, dizziness, dehydration. Renal-Renal toxicity increases with hypovolemia, CHF. Evaluate renal function prior to initiation and monitor periodically. Dosage adjustment recommended with eGFR<60 mL/min/1.73 m2. Not recommended with persistent eGFR <45 mL/min/1.73 m2 and is contraindicated with eGFR<30 mL/min/1.73 m2. Musculoskeletal-Monitor bone mineral density in osteopenia/osteoporosis. Bone fractures have occurred.
Giving canagliflozin tablet to a child under 12:
management or monitoring precaution: No safety and efficacy established in pediatrics.